Loading...
Market
Where will the next major phage therapy clinical trial be located by end of 2024?
5
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
India • 25%
ClinicalTrials.gov or equivalent international trial registries
Story
New Study Shows 77.2% Improvement, 61% Eradication in Phage Therapy for 100 Cases
Jun 4, 2024, 05:39 PM
A new study published in Nature Microbiology reveals the outcomes of personalized bacteriophage therapy for 100 consecutive cases. Conducted by a Belgian consortium, the multicenter, multinational, retrospective observational study highlights a 77.2% clinical improvement rate and a 61% eradication rate in tough-to-treat salvage cases. The research, led by Paul Pirnay and his team, marks their 30th joint publication and underscores two decades of dedication to making phage therapy a viable treatment option. The study provides an objective measure of the success rate for phage therapy.
View original story
Similar markets
United States • 25%
United Kingdom • 25%
Germany • 25%
Japan • 25%
USA • 25%
China • 25%
Germany • 25%
UK • 25%
Continue development • 33%
Discontinue program • 33%
Partner with another company • 33%
McMaster University • 33%
Stanford University • 33%
Queensland University of Technology • 33%
0-5 • 25%
6-10 • 25%
11-20 • 25%
More than 20 • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%